Hiring Senior Executives for Healthcare and Life Sciences: A Complete UK Guide

Hiring Senior Executives for Healthcare and Life Sciences: A Complete UK Guide

Healthcare and life sciences is among the most distinctive sectors for UK senior hiring. The combination of substantial regulatory complexity, scientific and clinical depth requirements, long product-development cycles, complex stakeholder relationships (regulators, payers, clinicians, patients), and capital-intensive business models produces senior leadership demands that don’t have direct parallels in other sectors. The sub-sector range is also genuinely broad — pharmaceuticals, medical devices, diagnostics, digital health, biotech, clinical research organisations, healthcare services, NHS-adjacent commissioning and consultancy — with each sub-sector drawing from a different candidate pool and operating under different regulatory and commercial dynamics. UK healthcare and life sciences senior hiring fails at materially higher rates when the sub-sector specifics are not properly worked through at the brief stage. The successful appointments are those calibrated to the specific sub-sector context from the start.

This guide is written for chairs, CEOs, founders, board members and investors approaching senior hiring at UK healthcare and life sciences firms. It covers the major sub-sectors, the regulatory dimensions, the senior team typically required, the candidate pool, compensation considerations, and the common pitfalls. For our healthcare and life sciences recruitment service, see healthcare and life sciences executive recruitment. For role-specific senior hiring guides, see our Knowledge Centre.

The major UK healthcare and life sciences sub-sectors

The sector divides into seven sub-sectors with substantively different commercial dynamics, regulatory environments and candidate pools.

Pharmaceuticals. Drug discovery, development and commercialisation. Typically large global firms (Big Pharma) plus a meaningful UK mid-market and emerging-pharma segment. Long product-development cycles (10+ years from discovery to market), substantial regulatory complexity (MHRA, EMA, FDA), and capital-intensive business models. Senior hiring typically emphasises substantive scientific or clinical credentials alongside commercial track record.

Biotech. Earlier-stage drug discovery and development firms, often venture-backed or recently listed. The business model differs from established pharma — typically focused on a smaller pipeline, with senior team quality being one of the dominant value drivers. Senior hiring emphasises scientific credentials, prior biotech operating experience, and capital markets fluency.

Medical devices. Diagnostics, surgical instruments, monitoring equipment, implantable devices. Different regulatory pathway from pharma (MDR, FDA 510(k) and PMA), shorter product cycles, and different commercial dynamics (often selling to hospital procurement and clinician decision-makers rather than payers directly).

Digital health. Software, AI, telemedicine, digital therapeutics, health data platforms. The sub-sector that has grown fastest in the UK over the past decade. Senior hiring blends technology and digital credentials with healthcare domain expertise — strong candidates typically have substantive experience of both.

Diagnostics. Laboratory testing, imaging, in vitro diagnostics, genetic testing. Both clinical-laboratory firms and diagnostic device manufacturers. The sub-sector grew substantially during and after the pandemic.

Clinical research organisations (CROs) and contract development. Service providers to pharma and biotech for clinical trial conduct, regulatory work, and contract development manufacturing. UK has substantial mid-market CRO activity.

Healthcare services. Care home operators, private hospital groups, primary care groups, occupational health providers, NHS-adjacent service businesses. Different commercial dynamics from product-led healthcare — typically labour-intensive, payer-driven, with regulatory environment focused on care quality and conduct.

Regulatory dimensions

UK healthcare and life sciences senior hiring intersects with multiple regulatory frameworks that shape role specifications.

MHRA (Medicines and Healthcare products Regulatory Agency). The UK regulator for pharmaceuticals, medical devices and clinical trials. Senior roles in pharma, biotech and medical devices typically warrant substantive regulatory familiarity. The MHRA’s post-Brexit operating model continues to evolve, with regulatory strategy a meaningful senior leadership dimension.

FDA, EMA and other international regulators. UK firms with international product reach require senior leadership with experience of multiple regulatory frameworks, particularly FDA for US-bound products and EMA for European market access.

NICE (National Institute for Health and Care Excellence). UK health technology assessment. Reimbursement dynamics shape commercial strategy for products targeting the NHS market.

CQC (Care Quality Commission). Regulator for health and care services in England. Senior hiring at care provider firms typically requires CQC framework familiarity.

HRA (Health Research Authority). UK governance for clinical research. Relevant for CRO, biotech and pharma senior leadership where clinical research is core.

The senior team in healthcare and life sciences firms

The composition of the senior team varies by sub-sector and firm stage. Six roles recur as common appointments.

CEO. Typically requires substantive sector experience plus the standard CEO dimensions (commercial leadership, board engagement, capital markets). Pharma and biotech CEOs typically come from senior commercial roles within the sector; digital health CEOs may come from technology backgrounds with healthcare domain expertise. See our How to Hire a CEO guide.

CMO (Chief Medical Officer). A specific role in pharma, biotech, medical devices and digital health firms — the senior clinical leader, typically a qualified medical doctor with substantive clinical and pharmaceutical/device development experience. Distinct from the corporate Chief Marketing Officer (also CMO). The clinical CMO is typically responsible for the clinical strategy, regulatory engagement on clinical matters, and clinical credibility of the firm’s products.

Chief Scientific Officer. Often appointed alongside or in place of a clinical CMO — the senior scientific leader, particularly in pre-commercial biotech and emerging pharma firms.

CFO. Healthcare and life sciences CFOs typically require sector-specific capital markets experience (where listed), regulatory financial reporting awareness, and (for pharma and biotech) experience of milestone-driven capital structures. Cross-portfolio with FD Capital where CFO is the primary seat — see our sister firm FD Capital.

Chief Commercial Officer. Particularly central in established pharma, biotech approaching launch, and medical devices firms. The CCO leads market access, payer relationships, and commercial strategy. See our How to Hire a Chief Commercial Officer guide.

Head of Regulatory Affairs. Senior regulatory leader, typically reporting to the CEO or COO, with substantive prior regulatory authority engagement. The role is the firm’s senior interface with MHRA, FDA, EMA and equivalent bodies.

The candidate pool

The UK healthcare and life sciences senior candidate pool is sector-deep but tight across most sub-sectors. Five pools recur.

Sitting senior executives at peer firms. The most common pool, with sub-sector specificity meaningful. Strong CEOs at large pharma firms differ from strong CEOs at biotech firms; strong commercial leaders at medical devices firms differ from strong commercial leaders at digital health firms.

Step-up candidates from larger global pharma. The natural growth pool, particularly for CEO, CFO and CCO appointments at UK mid-market firms. Senior figures from Big Pharma stepping into smaller firms with broader scope.

Cross-sub-sector candidates. Senior candidates moving between sub-sectors — pharma to biotech is common; digital health to medical devices less so. The pool warrants assessment of whether the cross-sub-sector transition matches what the firm specifically needs.

Big Four and consulting transitions. Senior partners from healthcare-focused practices at Big Four and specialist consultancies (typically transitioning into in-house commercial or strategy roles).

Clinical and scientific specialists with commercial credentials. Particularly for CMO and CSO roles. Senior clinicians or scientists with substantive prior commercial experience in pharma, biotech or medical devices.

Compensation

UK healthcare and life sciences senior compensation typically commands premiums above general benchmarks reflecting sector-specific commercial complexity and regulatory exposure. Broad ranges:

Mid-market pharma and biotech CEO £350-700k base, CFO £280-500k, CMO/CSO £300-550k, CCO £280-500k. Variable typically 40-60% of base. Equity participation typically substantial (especially for biotech where management equity is often a dominant economic driver).

Established UK-listed pharma and medical devices CEO £600k-£1.5m+, CFO £400-800k, CCO £350-700k, CMO £400-750k. LTI structures substantial and shareholder-approved.

Digital health and growth-stage biotech compensation often equity-heavier than fee-heavier. Strong candidates evaluate the equity structure substantively.

For substantive treatment of compensation structures, see our Executive Compensation guide and Equity and Incentives guide.

Common healthcare and life sciences search pitfalls

Six patterns recur. Insufficient sub-sector specificity in the brief. Underestimating regulatory dimension — strong candidates at this level expect senior search firms to have substantive understanding of the regulatory landscape. Mixing scientific/clinical and commercial track records — different candidates fit different role weightings. Compensation envelopes anchored on cross-sector benchmarks rather than sector-specific norms. Underestimating capital markets dimension for listed and pre-IPO firms. Cultural mismatches between candidates from different sub-sectors that look superficially aligned.

How Exec Capital approaches healthcare and life sciences mandates

Exec Capital runs healthcare and life sciences senior searches with sub-sector specifics worked through at the brief stage. The substantive credentials dimension — scientific, clinical, regulatory and commercial track record — receives the same rigour we bring to any senior search, with sector-specific assessment building in alongside. We work on a retained basis, with engagement running through to the candidate’s first day in role.

For boards beginning healthcare or life sciences senior search, building out senior teams for growth-stage firms in the sector, or working through specific sub-sector questions, we offer a structured initial conversation. Every senior healthcare and life sciences mandate is led personally by Adrian Lawrence FCA.

Further reading

For our healthcare and life sciences recruitment service, see healthcare and life sciences executive recruitment. For role-specific senior hiring guides, see our How to Hire a CEO guide, How to Hire a Chief Commercial Officer guide, and the rest in our Knowledge Centre.

For senior pharma, biotech and medical devices CFO appointments where FD Capital’s specialism is concentrated, see our sister firm FD Capital. For related methodology guides, see our Executive Search Methodology guide, Executive Compensation guide, and Equity and Incentives guide.

For UK healthcare and life sciences regulatory frameworks, see the MHRA, the National Institute for Health and Care Excellence (NICE), the Care Quality Commission (CQC), and the Health Research Authority (HRA). For UK life sciences industry context, see the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA).